Literature DB >> 19333918

Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology.

Duska Dragun, Jörg H W Distler, Gabriela Riemekasten, Oliver Distler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19333918     DOI： 10.1002/art.24364

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  14 in total

Review 1.  Functional autoantibodies in systemic sclerosis.

Authors:  Jeannine Günther; Judith Rademacher; Jakob M van Laar; Elise Siegert; Gabriela Riemekasten
Journal:  Semin Immunopathol       Date:  2015-08-21       Impact factor: 9.623

Review 2.  Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.

Authors:  Naoki Iwamoto; Jörg H W Distler; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 3.  Functional autoantibodies in systemic sclerosis pathogenesis.

Authors:  Angela Kill; Gabriela Riemekasten
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

4.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

Review 5.  Coagulation and autoimmunity in scleroderma interstitial lung disease.

Authors:  Anna Ludwicka-Bradley; Richard M Silver; Galina S Bogatkevich
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

Review 6.  Imatinib and the treatment of fibrosis: recent trials and tribulations.

Authors:  Jessica Gordon; Robert Spiera
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

7.  Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.

Authors:  Kristin Baird; Leora E Comis; Galen O Joe; Seth M Steinberg; Fran T Hakim; Jeremy J Rose; Sandra A Mitchell; Steven Z Pavletic; William D Figg; Lawrence Yao; Kathleen C Flanders; Naoko Takebe; Stefanie Sarantopoulos; Susan Booher; Edward W Cowen
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-12       Impact factor: 5.742

Review 8.  [Scleroderma].

Authors:  O Distler; S Gay
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

9.  Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Authors:  Robert F Spiera; Jessica K Gordon; Jamie N Mersten; Cynthia M Magro; Mansi Mehta; Horatio F Wildman; Stacey Kloiber; Kyriakos A Kirou; Stephen Lyman; Mary K Crow
Journal:  Ann Rheum Dis       Date:  2011-03-11       Impact factor: 19.103

10.  Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.

Authors:  Jessica Gordon; Robert Spiera
Journal:  Int J Rheumatol       Date:  2011-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.